-
Precision Oncology in Melanoma: Changing Practices J Nucl. Med. (IF 9.1) Pub Date : 2024-11-14 Sean C. Dougherty, William L. Flowers, Elizabeth M. Gaughan
Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis for metastatic melanoma was poor because of limited treatment options. However, after multiple landmark clinical trials displaying the efficacy of combined BRAF/MEK inhibition for BRAF-mutant melanoma and
-
Value of [68Ga]Ga-NYM046 PET/CT, in Comparison with 18F-FDG PET/CT, for Diagnosis of Clear Cell Renal Cell Carcinoma J Nucl. Med. (IF 9.1) Pub Date : 2024-11-14 Kequan Lou, Jialiang Wang, Huihui He, Yanjuan Wang, Yuanyuan Mi, Wenjin Li, Liping Chen, Yu Zhang, Yong Mao, Jianguo Lin, Haitian Fu, Chunjing Yu
Visual Abstract
-
[11C]PS13 Demonstrates Pharmacologically Selective and Substantial Binding to Cyclooxygenase-1 in the Human Brain J Nucl. Med. (IF 9.1) Pub Date : 2024-11-14 Nafiseh Ghazanfari, Jeih-San Liow, Min-Jeong Kim, Raven Cureton, Adrian Lee, Carson Knoer, Madeline Jenkins, Jinsoo Hong, Jose A. Montero Santamaria, H. Umesha Shetty, Anthony Galassi, Paul Wighton, Martin Nørgaard, Douglas N. Greve, Sami S. Zoghbi, Victor W. Pike, Robert B. Innis, Paolo Zanotti-Fregonara
Our laboratory recently developed [11C]PS13 as a PET radioligand to selectively measure cyclooxygenase-1 (COX-1). The cyclooxygenase enzyme family converts arachidonic acid into prostaglandins and thromboxanes, which mediate inflammation. The total brain uptake of [11C]PS13, which is composed of both specific binding and background uptake, can be accurately quantified with gold standard methods of
-
Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study J Nucl. Med. (IF 9.1) Pub Date : 2024-11-14 Lyduine E. Collij, Gérard N. Bischof, Daniele Altomare, Ilse Bader, Mark Battle, David Vállez García, Isadora Lopes Alves, Robin Wolz, Rossella Gismondi, Andrew Stephens, Zuzana Walker, Philip Scheltens, Agneta Nordberg, Juan Domingo Gispert, Alexander Drzezga, Andrés Perissinotti, Silvia Morbelli, Christopher Buckley, Valentina Garibotto, Giovanni B. Frisoni, Gill Farrar, Frederik Barkhof
Visual Abstract
-
Immuno-PET/CT Imaging of Trop2 with [18F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation J Nucl. Med. (IF 9.1) Pub Date : 2024-11-14 Wei Huang, Min Cao, Yanfei Wu, You Zhang, Shuxian An, Xinbing Pan, Xinyuan Zhou, Hongda Shao, Yihui Guan, Gang Huang, Fabrizia Gelardi, Arturo Chiti, Fang Xie, Jianjun Liu, Weijun Wei
Immuno-PET/CT imaging, a branch of molecular imaging, can noninvasively and specifically visualize biomarker expression across the body. Trophoblast cell surface antigen 2 (Trop2) is a pan-cancer biomarker and plays a crucial role in tumorigenesis through multiple signaling pathways. The study aims to develop and translate novel Trop2 single-domain antibody (sdAb) tracers for clinical use. Methods:
-
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG–Avid Discordant Findings J Nucl. Med. (IF 9.1) Pub Date : 2024-11-14 Ridvan Arda Demirci, Alireza Ghodsi, Roman Gulati, Sanaz Behnia, Peter S. Nelson, Heather H. Cheng, Todd A. Yezefski, Michael C. Haffner, Jessica E. Hawley, Robert B. Montgomery, Evan Y. Yu, Michael T. Schweizer, Delphine L. Chen, Amir Iravani
The VISION and TheraP trials introduced different PET-based criteria for patient selection for treatment with 177Lu-PSMA-617 (LuPSMA). TheraP used a higher prostate-specific membrane antigen (PSMA) uptake threshold than VISION and required 18F-FDG PET to exclude patients with discordant findings. Although the screen-failed patients had shorter overall survival (OS) than those treated with LuPSMA, it
-
Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer J Nucl. Med. (IF 9.1) Pub Date : 2024-11-14 Mike Wenzel, Florestan Koll, Benedikt Hoeh, Clara Humke, Carolin Siech, Nicolai Mader, Amir Sabet, Daniel Groener, Thomas Steuber, Markus Graefen, Tobias Maurer, Christian Brandts, Severine Banek, Felix K.H. Chun, Philipp Mandel
177Lu-vipivotide tetraxetan prostate-specific membrane antigen (177Lu-PSMA) therapy is under current scientific investigation and aims to become established in the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, real-world evidence in treatment comparison is scant. Methods: We relied on the FRAMCAP database and compared cabazitaxel versus 177Lu-PSMA therapy in mCRPC patients
-
Performance Characteristics of a New Generation 148-cm Axial Field-of-View uMI Panorama GS PET/CT System with Extended NEMA NU 2-2018 and EARL Standards J Nucl. Med. (IF 9.1) Pub Date : 2024-11-07 Haiqiong Zhang, Chao Ren, Yu Liu, Xinchun Yan, Meixi Liu, Zhixin Hao, Haiqun Xing, Li Huo
Visual Abstract
-
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617 J Nucl. Med. (IF 9.1) Pub Date : 2024-11-07 Ridvan Arda Demirci, Roman Gulati, Jessica E. Hawley, Todd Yezefski, Michael C. Haffner, Heather H. Cheng, Robert B. Montgomery, Michael T. Schweizer, Evan Y. Yu, Peter S. Nelson, Delphine L. Chen, Amir Iravani
177Lu-PSMA-617 (LuPSMA) is a newly established treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), but survival outcomes vary widely, and predictors of treatment responses are needed. This study investigated the role of total tumor volumes (TTVs) and new lesions (NLs) determined by LuPSMA SPECT/CT in early cycles to predict subsequent outcomes in a real-world practice
-
CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A Translational Study J Nucl. Med. (IF 9.1) Pub Date : 2024-11-07 Xiang Zhou, Qianyun Wu, Wei Zhai, You Zhang, Yanfei Wu, Min Cao, Cheng Wang, Yihui Guan, Jianjun Liu, Fang Xie, Weijun Wei
The diagnosis and surveillance of clear cell renal cell carcinoma (ccRCC) remains a clinical challenge. The high and specific expression of the cluster of differentiation 70 (CD70) in ccRCC makes it a potential diagnostic and therapeutic target. Methods: We detected and analyzed CD70 expression in various renal cell carcinomas (RCCs) and normal kidneys using immunohistochemical staining. Two novel
-
International Metabolic Prognostic Index Is Superior to Other Metabolic Tumor Volume–Based Prognostication Methods in a Real-Life Cohort of Diffuse Large B-Cell Lymphoma J Nucl. Med. (IF 9.1) Pub Date : 2024-11-07 Vibeke K.J. Vergote, Gregor Verhoef, Ann Janssens, F.J. Sherida H. Woei-a-jin, Wies Deckers, Annouschka Laenen, Thomas Tousseyn, Daan Dierickx, Christophe M. Deroose
Baseline metabolic tumor volume (MTV) is a promising prognostic marker in diffuse large B-cell lymphoma (DLBCL). We assessed the prognostic value of 4 novel metabolic risk scores in a real-life DLBCL cohort and compared them with the revised international prognostic index (IPI). Methods: We included a consecutive series of untreated DLBCL, not otherwise specified cases that were diagnosed in our hospital
-
MIRD Pamphlet No. 30: MIRDfit—A Tool for Fitting of Biodistribution Time–Activity Data for Internal Dosimetry J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Lukas M. Carter, Juan Camilo Ocampo Ramos, Seval Beykan Schuerrle, Harry Marquis, Michael Lassmann, Wesley E. Bolch, Adam L. Kesner
In nuclear medicine, estimating the number of radioactive decays that occur in a source organ per unit administered activity of a radiopharmaceutical (i.e., the time-integrated activity coefficient [TIAC]) is an essential task within the internal dosimetry workflow. TIAC estimation is commonly derived by least-squares fitting of various exponential models to organ time–activity data (radiopharmaceutical
-
Validation of an Artificial Intelligence–Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Maria C. Ferrández, Sandeep S.V. Golla, Jakoba J. Eertink, Sanne E. Wiegers, Gerben J.C. Zwezerijnen, Martijn W. Heymans, Pieternella J. Lugtenburg, Lars Kurch, Andreas Hüttmann, Christine Hanoun, Ulrich Dührsen, Sally F. Barrington, N. George Mikhaeel, Luca Ceriani, Emanuele Zucca, Sándor Czibor, Tamás Györke, Martine E.D. Chamuleau, Josée M. Zijlstra, Ronald Boellaard
The aim of this study was to validate a previously developed deep learning model in 5 independent clinical trials. The predictive performance of this model was compared with the international prognostic index (IPI) and 2 models incorporating radiomic PET/CT features (clinical PET and PET models). Methods: In total, 1,132 diffuse large B-cell lymphoma patients were included: 296 for training and 836
-
The Updated Registry of Fast Myocardial Perfusion Imaging with Next-Generation SPECT (REFINE SPECT 2.0) J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Robert J.H. Miller, Mark Lemley, Aakash Shanbhag, Giselle Ramirez, Joanna X. Liang, Valerie Builoff, Paul Kavanagh, Tali Sharir, M. Timothy Hauser, Terrence D. Ruddy, Mathews B. Fish, Timothy M. Bateman, Wanda Acampa, Andrew J. Einstein, Sharmila Dorbala, Marcelo F. Di Carli, Attila Feher, Edward J. Miller, Albert J. Sinusas, Julian Halcox, Monica Martins, Philipp A. Kaufmann, Damini Dey, Daniel S
The Registry of Fast Myocardial Perfusion Imaging with Next-Generation SPECT (REFINE SPECT) has been expanded to include more patients and CT attenuation correction imaging. We present the design and initial results from the updated registry. Methods: The updated REFINE SPECT is a multicenter, international registry with clinical data and image files. SPECT images were processed by quantitative software
-
Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Masatoshi Hotta, Grace Hyun J. Kim, Vilasinee Rerkpichaisuth, Pang Yu Teng, Wesley R. Armstrong, Giuseppe Carlucci, Magnus Dahlbom, Fereidoun Abtin, Shahrzad M. Lari, Gregory A. Fishbein, Johannes Czernin, Elizabeth R. Volkmann, S. Sam Weigt, Jeremie Calais
Recent studies have demonstrated promising results of fibroblast activation protein (FAP) inhibitor (FAPI) PET in prognosticating and monitoring interstitial lung diseases (ILDs). As a first step toward successful translation, our primary aim was to validate the FAPI PET uptake through immunohistochemistry in patients with advanced ILD who underwent lung transplantation after a FAPI PET scan. Methods:
-
Summary: Appropriate Use Criteria for the Use of Nuclear Medicine in Fever of Unknown Origin J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Christopher J. Palestro, Gad Abikhzer, Zvi Bar-Sever, Twyla Bartel, Rebecca Brady, Erin E. Grady, Ora Israel, Sanjay K. Jain, Sheetal Kandiah, Machaba M. Sathekge, Barry L. Shulkin
The diagnostic work-up of patients with fever of unknown origin (FUO) begins with a thorough history and physical examination, complete blood count with differential, chest x-ray, urinalysis and culture, electrolyte panel, liver enzymes, erythrocyte sedimentation rate, and C-reactive protein level. Additional imaging procedures, including nuclear medicine tests, are generally used as second-line procedures
-
Validation of a Simplified Tissue-to-Reference Ratio Measurement Using SUVR to Assess Synaptic Density Alterations in Alzheimer Disease with [11C]UCB-J PET J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Juan J. Young, Ryan S. O’Dell, Mika Naganawa, Takuya Toyonaga, Ming-Kai Chen, Nabeel B. Nabulsi, Yiyun Huang, Emma Cooper, Alyssa Miller, Jessica Lam, Kara Bates, Audrey Ruan, Kimberly Nelsen, Elaheh Salardini, Richard E. Carson, Christopher H. van Dyck, Adam P. Mecca
Simplified methods of acquisition and quantification would facilitate the use of synaptic density imaging in multicenter and longitudinal studies of Alzheimer disease (AD). We validated a simplified tissue-to-reference ratio method using SUV ratios (SUVRs) for estimating synaptic density with [11C]UCB-J PET. Methods: Participants included 31 older adults with AD and 16 with normal cognition. The distribution
-
Evaluation of Fibroblast Activation Protein Expression Using 68Ga-FAPI46 PET in Hypertension-Induced Tissue Changes J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Jung Woo Byun, Jin Chul Paeng, Young Ju Kim, Seung-Pyo Lee, Yun-Sang Lee, Hongyoon Choi, Keon Wook Kang, Gi Jeong Cheon
Chronic hypertension leads to injury and fibrosis in major organs. Fibroblast activation protein (FAP) is one of key molecules in tissue fibrosis, and 68Ga-labeled FAP inhibitor-46 (FAPI46) PET is a recently developed method for evaluating FAP. The aim of this study was to evaluate FAP expression and fibrosis in a hypertension model and to test the feasibility of 68Ga-FAPI46 PET in hypertension. Methods:
-
Preclinical Investigation of [212Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Amal Saidi, Tania A. Stallons, Amy G. Wong, Julien J. Torgue
The role of gastrin-releasing peptide receptor (GRPR) in various diseases, including cancer, has been extensively studied and has emerged as a promising therapeutic target. In this study, we successfully achieved the use of [212Pb]Pb-DOTAM-GRPR1, comprising the α-particle generator, 212Pb, combined with a GRPR-targeting peptide, GRPR1, in a prostate cancer model. Methods: Pharmacokinetics, toxicity
-
Preclinical Evaluation of 226Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Helena Koniar, Luke Wharton, Aidan Ingham, Ana Paulina Morales Oliver, Helen Merkens, Cristina Rodríguez-Rodríguez, Peter Kunz, Valery Radchenko, Hua Yang, Arman Rahmim, Carlos Uribe, Paul Schaffer
226Ac (t1/2 = 29.37 h) has been proposed as a theranostic radioisotope leveraging both its diagnostic -emissions and therapeutic α-emissions. 226Ac emits 158 and 230 keV -photons ideal for quantitative SPECT imaging and acts as an in vivo generator of 4 high-energy α-particles. Because of these nuclear decay properties, 226Ac has potential to act as a standalone theranostic isotope. In this proof-of-concept
-
Routine Use of [64Cu]Cu-DOTATATE PET/CT in a Neuroendocrine Tumor Center: Referral Patterns and Image Results of 2,249 Consecutive Scans J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Esben Andreas Carlsen, Mathias Loft, Camilla Bardram Johnbeck, Ulrich Knigge, Seppo W. Langer, Jann Mortensen, Lotte Enevoldsen, Peter Oturai, Andreas Kjaer
The role of somatostatin receptor (SSTR) PET/CT, using 68Ga-based tracers or [64Cu]Cu-DOTATATE (64Cu-DOTATATE), in the management of patients with neuroendocrine neoplasm (NEN) is guided by appropriate use criteria (AUC). In this study, we performed systematic analyses of referral patterns and image findings of routine 64Cu-DOTATATE PET/CT scans to support AUC development. Methods: We included all
-
Cardiac Neuroendocrine Tumor Metastases on 68Ga-DOTATATE PET/CT: Identification and Prognostic Significance J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Hwan Lee, Ahmad S. Alhamshari, Vandan Patel, Abhijit Bhattaru, Chaitanya Rojulpote, Mahesh K. Vidula, Daniel A. Pryma, Paco E. Bravo
Neuroendocrine tumor (NET) metastases to the heart are found in 1%–4% of NET patients and have been reported primarily in the form of individual cases. We investigated the prevalence, clinical characteristics, imaging features, and outcomes of NET patients with cardiac metastases on 68Ga-DOTATATE PET/CT. Methods: 68Ga-DOTATATE PET/CT of 490 consecutive patients from a single institution were retrospectively
-
Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Vishnu Murthy, Andrew F. Voter, Kathleen Nguyen, Martin Allen-Auerbach, Lucia Chen, Sydney Caputo, Elisa Ledet, Abraham Akerele, Abuzar Moradi Tuchayi, Courtney Lawhn-Heath, Tingchang Wang, Michael A. Carducci, Martin G. Pomper, Channing J. Paller, Johannes Czernin, Lilja B. Solnes, Thomas A. Hope, Oliver Sartor, Jeremie Calais, Andrei Gafita
The phase 3 VISION trial demonstrated that [177Lu]Lu-PSMA-617 prolonged progression-free survival and overall survival (OS) in prostate-specific membrane antigen [PSMA]–positive metastatic castration-resistant prostate cancer (mCRPC) patients who progressed on taxane-based chemotherapy and androgen receptor–signaling inhibitors (ARSIs). The U.S. expanded-access program (EAP; NCT04825652) was opened
-
Association of Free-to-Total PSA Ratio and 18F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Rui M. Bernardino, Katherine Lajkosz, Leyi B. Yin, Rashid K. Sayyid, Marian Wettstein, Harkanwal Randhawa, Jessica G. Cockburn, Sayeed Ahmed, Rosita Thomassian, Eleftherios Diamandis, Ur Metser, Alejandro Berlin, Neil E. Fleshner
In Canada and across the globe, access to PSMA PET/CT is limited and expensive. For patients with biochemical recurrence (BCR) after treatment for prostate cancer, novel strategies are needed to better stratify patients who may or may not benefit from a PSMA PET scan. The role of the free-to-total prostate-specific antigen (PSA) ratio (FPSAR) in posttreatment prostate cancer, specifically in the PSMA
-
Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Andrei Gafita, Andrew Voter, Somya Shesadri, Avery Spitz, Catherine H. Marshall, Steven P. Rowe, Mark C. Markowski, Martin G. Pomper, A. Cahid Civelek, Michael A. Carducci, Samuel R. Denmeade, Jeffrey Young, Kenneth J. Pienta, Channing J. Paller, Lilja B. Solnes
[177Lu]Lu-PSMA-617 was approved by the U.S. Food and Drug Administration for patients with prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC). Since the time of regulatory approval, however, real-world data have been lacking. This study investigated the efficacy, safety, and outcome predictors of [177Lu]Lu-PSMA-617 at a major U.S. academic center
-
uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Edwin C. Pratt, Riccardo Mezzadra, Amanda Kulick, Spencer Kaminsky, Zachary V. Samuels, Angelique Loor, Elisa de Stanchina, Scott W. Lowe, Jason S. Lewis
Identifying cancer therapy resistance is a key time-saving tool for physicians. Part of chemotherapy resistance includes senescence, a persistent state without cell division or cell death. Chemically inducing senescence with the combination of trametinib and palbociclib (TP) yields several tumorigenic and prometastatic factors in pancreatic cancer models with many potential antibody-based targets.
-
Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Frédéric Pouliot, Fred Saad, Etienne Rousseau, Patrick O. Richard, Atefeh Zamanian, Stephan Probst, Éric Lévesque, Vincent Castonguay, Nicolas Marcoux, Michele Lodde, Daniel Juneau, Zineb Hamilou, Jean-Baptiste Lattouf, François-Alexandre Buteau, Michel Pavic, Jean-François Castilloux, Bertrand Neveu, Guillaume F. Bouvet, Catherine Allard, Amélie Tétu, Brigitte Guérin, Jean-Mathieu Beauregard, for
Intrapatient intermetastatic heterogeneity (IIH) has been demonstrated in metastatic castration-resistant prostate cancer (mCRPC) patients and is of the utmost importance for radiopharmaceutical therapy (RPT) eligibility. This study was designed to determine the prevalence of IIH and RPT eligibility in mCRPC patients through a triple-tracer PET imaging strategy. Methods: This was a multisite prospective
-
[18F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Yinjun Dong, Zhendan Wang, Xinying Hu, Yuhong Sun, Jingjie Qin, Qiming Qin, Shuguang Liu, Shuanghu Yuan, Jinming Yu, Yuchun Wei
This single-center, single-arm, phase II trial (ChiCTR2100050057) investigated the ability of 18F-labeled fibroblast activation protein inhibitor ([18F]AlF-NOTA-FAPI-04, denoted as 18F-FAPI) PET/CT to predict the response to neoadjuvant camrelizumab plus chemotherapy (nCC) in locally advanced esophageal squamous cell carcinoma (LA-ESCC). Methods: This study included 32 newly diagnosed LA-ESCC participants
-
Granzyme B PET/CT Imaging Evaluates Early Response to Immunotherapy in Gastric Cancer J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Qiufang Liu, Xiaoping Xu, Ziyi Yang, Jianping Zhang, Jindian Li, Ying Qiao, Silong Hu, Xiaosheng Liu, Weijian Guo, Shaoli Song
In several malignancies, only a limited number of patients respond to immune checkpoint inhibitors. Predicting and monitoring responses to these inhibitors represent an unmet clinical need. Here, we developed a PET/CT probe targeting granzyme B, [68Ga]Ga-NOTA-Gly-Gly-Gly-Ile-Glu-Pro-Asp-CHO (GSI), and aimed to investigate whether it can be used to monitor the effects of immune checkpoint inhibitors
-
Impact of 18F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Jeongryul Ryu, Jaewon Hyung, Sangwon Han, Jae Ho Jeong, Sae Byul Lee, Tae-Kyung Robyn Yoo, Jisun Kim, Hee Jeong Kim, Il Yong Chung, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Hyehyun Jeong, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim, Dae Hyuk Moon
The clinical impact of 16α-18F-fluoro-17β-estradiol (18F-FES) PET/CT on patient management has not been well investigated. The aim of this study was to assess the clinical impact of 18F-FES PET/CT on the management of patients with recurrent or metastatic breast cancer. Methods: Study subjects were identified retrospectively from a database of a prospective trial for postmarketing surveillance of 18F-FES
-
Precautions to Consider in the Analysis of Prognostic and Predictive Indices J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Loïc Chartier, Aurélien Belot, Isabelle Chaillol, Mad-Hélénie Elsensohn, Cédric Portugues, Marguerite Fournier, Clémentine Joubert, Elodie Gat, Cécile Pizot, Patrick Fogarty, Tesla Murairi, Romain Ould Ammar, Jérôme Paget, Fanny Cherblanc, Romain Ricci, Laetitia Vercellino, Salim Kanoun, Anne-Ségolène Cottereau, Catherine Thieblemont, Olivier Casasnovas
Understanding the differences between prognostic and predictive indices is imperative for medical research advances. We have developed a new prognostic measure that will identify the strengths, limitations, and potential applications in clinical practice.
-
Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01 Jeremie Calais, Michael J. Morris, Ayse Tuba Kendi, Arash Rezazadeh Kalebasty, Ronald Tutrone, Michael J. Anderson, Oliver Sartor
Optimal patient management protocols for metastatic castration-resistant prostate cancer (mCRPC) are poorly defined and even further complexified with new therapy approvals, such as radiopharmaceuticals. The prostate-specific membrane antigen (PSMA)–targeted agent 177Lu vipivotide tetraxetan ([177Lu]Lu-PSMA-617), approved after the phase III VISION study, presents physicians with additional aspects
-
Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer J Nucl. Med. (IF 9.1) Pub Date : 2024-10-30 Mina Swiha, Sarennya Pathmanandavel, Nathan Papa, Zahra Sabahi, Sherrington Li, Alex Zheng, Sobia Khan, Maria Ayers, Shikha Sharma, Megan Crumbaker, Andrew Nguyen, Lyn Chan, Narjess Ayati, Louise Emmett
[177Lu]Lu-prostate-specific membrane antigen (PSMA) is an effective treatment for metastatic castration-resistant prostate cancer (mCRPC). [177Lu]Lu-PSMA SPECT/CT 24 h after injection has shown potential as a response biomarker for [177Lu]Lu-PSMA therapy but is not convenient for patients. This study investigated 4-h [177Lu]Lu-PSMA SPECT/CT as an alternative to 24-h [177Lu]Lu-PSMA SPECT/CT for evaluation
-
Comparison Between Brain and Cerebellar Autoradiography Using [18F]Flortaucipir, [18F]MK6240, and [18F]PI2620 in Postmortem Human Brain Tissue J Nucl. Med. (IF 9.1) Pub Date : 2024-10-30 Antonio Aliaga, Joseph Therriault, Kely Monica Quispialaya, Arturo Aliaga, Robert Hopewell, Nesrine Rahmouni, Arthur C. Macedo, Peter Kunach, Jean-Paul Soucy, Gassan Massarweh, Aida Abreu Diaz, Tharick A. Pascoal, Andreia Rocha, Marie-Christine Guiot, Luiza S. Machado, Marco Antônio De Bastiani, Débora Guerini de Souza, Diogo O. Souza, Serge Gauthier, Eduardo R. Zimmer, Pedro Rosa-Neto
Our objective was to evaluate the in vitro binding properties of [18F]flortaucipir, 6-(fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([18F]MK6240), and 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5c′]dipyridine ([18F]PI2620) head-to-head in postmortem human brain tissue. Methods: Autoradiography was used to assess uptake of [18F]flortaucipir, [18F]MK6240, and [18F]PI2620 in
-
Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu-PSMA-617 J Nucl. Med. (IF 9.1) Pub Date : 2024-10-30 Miguel Muniz, Oliver Sartor, Jacob J. Orme, Regina M. Koch, Hana R. Rosenow, Ahmed M. Mahmoud, Jack R. Andrews, Adam M. Kase, Irbaz B. Riaz, Gokce Belge Bilgin, Matthew P. Thorpe, A. Tuba Kendi, Geoffrey B. Johnson, Praful Ravi, Eugene D. Kwon, Daniel S. Childs
It is well known that patients with liver metastasis from metastatic castration-resistant prostate cancer have poor or only transient responses to many forms of systemic therapy. Data on outcomes after treatment with [177Lu]Lu-PSMA-617 (LuPSMA) are scarce. The VISION trial reports a hazard ratio for overall survival (OS) in the subgroup of patients with liver metastasis without disclosing the absolute
-
Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI J Nucl. Med. (IF 9.1) Pub Date : 2024-10-30 Ida Sonni, Adam B. Weiner, Sahith Doddipalli, Madhvi Deol, David Ban, Hye Ok Kim, Tristan Grogan, Preeti Ahuja, Nashla Barroso, Yang Zong, Priti Soin, Anthony Sisk, Johannes Czernin, William Hsu, Jeremie Calais, Robert E. Reiter, Steven S. Raman
Multiparametric MRI (mpMRI) and prostate-specific membrane antigen (PSMA) PET/CT are complementary imaging modalities used in the presurgical evaluation of patients with prostate cancer (PCa). The purpose of this study was to characterize clinically significant PCa (csPCa) detected and not detected by PSMA PET/CT and mpMRI, focusing on tumors detected solely by PSMA PET/CT and overlooked by mpMRI.
-
FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study J Nucl. Med. (IF 9.1) Pub Date : 2024-10-30 Rong Rong Huang, Chunlai Zuo, Christine E. Mona, Adrien Holzgreve, Colm Morrissey, Peter S. Nelson, Lauren Brady, Lawrence True, Anthony Sisk, Johannes Czernin, Jeremie Calais, Huihui Ye
Prostate-specific membrane antigen (PSMA) is a theranostic target for metastatic prostate cancer (PCa). However, castration-resistant PCa (CRPC) may lose PSMA expression after systemic therapy. Fibroblast activation protein (FAP), expressed by carcinoma-associated fibroblasts in various cancer types, including PCa, has the potential to be an alternative target. In this study, we evaluated FAP expression
-
Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate–Ribose) Polymerase-1–Targeted 18F-Fluorthanatrace PET in Breast Cancer J Nucl. Med. (IF 9.1) Pub Date : 2024-10-30 Anthony J. Young, Austin R. Pantel, Mahsa Kiani, Robert K. Doot, Sina Bagheri, Daniel A. Pryma, Michael D. Farwell, Shihong Li, Hsiaoju Lee, Erin K. Schubert, Anthony Secreto, Samantha P. Zuckerman, Anupma Nayak, Hoon Choi, Sean Carlin, Angela DeMichele, David A. Mankoff, Rong Zhou, Robert H. Mach, Elizabeth S. McDonald
The poly(adenosine diphosphate–ribose) polymerase inhibitors (PARPi) have demonstrated efficacy in ovarian, breast, and prostate cancers, but current biomarkers do not consistently predict clinical benefit. 18F-fluorthanatrace (18F-FTT) is an analog to rucaparib, a clinically approved PARPi, and is a candidate biomarker for PARPi response. This study intends to characterize 18F-FTT pharmacokinetics
-
[18F]FDG and [68Ga]Ga-FAPI-04–Directed Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine Neoplasms J Nucl. Med. (IF 9.1) Pub Date : 2024-10-30 Kerstin Michalski, Aleksander Kosmala, Philipp E. Hartrampf, Marieke Heinrich, Sebastian E. Serfling, Wiebke Schlötelburg, Andreas K. Buck, Alexander Meining, Rudolf A. Werner, Alexander Weich
Visual Abstract
-
Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors J Nucl. Med. (IF 9.1) Pub Date : 2024-10-30 Andreas Helisch, Clemens Kratochwil, Christian Kleist, Susanne Krämer, Juan Jose Rosales Castillo, Katharina Dendl, Hendrik Rathke, Isabelle von Goetze, Mathias Schreckenberger, Dirk Jäger, Thomas Lindner, Walter Mier, Frederik Giesel, Uwe Haberkorn, Manuel Röhrich
Radiopharmaceutical therapies (RPTs) based on fibroblast activation protein (FAP) and FAP inhibitors (FAPIs) are a new option for progressive metastatic cancer in patients pretreated multiple times. To date, published in-human data refer to initial experiences with β-emitting 90Y- and 177Lu-based RPT. However, the short tumor retention time of FAPI ligands is considered a major limitation of FAPI RPT
-
MIRD Pamphlet No. 31: MIRDcell V4—Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy J Nucl. Med. (IF 9.1) Pub Date : 2024-10-24 Sumudu Katugampola, Jianchao Wang, Roger W. Howell
Radiopharmaceutical cocktails have been developed over the years to treat cancer. Cocktails of agents are attractive because 1 radiopharmaceutical is unlikely to have the desired therapeutic effect because of nonuniform uptake by the targeted cells. Therefore, multiple radiopharmaceuticals targeting different receptors on a cell is warranted. However, past implementations in vivo have not met with
-
Modeling PET Data Acquired During Nonsteady Conditions: What If Brain Conditions Change During the Scan? J Nucl. Med. (IF 9.1) Pub Date : 2024-10-24 Evan D. Morris, Gaelle M. Emvalomenos, Jocelyn Hoye, Steven R. Meikle
Researchers use dynamic PET imaging with target-selective tracer molecules to probe molecular processes. Kinetic models have been developed to describe these processes. The models are typically fitted to the measured PET data with the assumption that the brain is in a steady-state condition for the duration of the scan. The end results are quantitative parameters that characterize the molecular processes
-
Head-to-Head Comparison of [68Ga]Ga-NOTA-RM26 and [18F]FDG PET/CT in Patients with Gastrointestinal Stromal Tumors: A Prospective Study J Nucl. Med. (IF 9.1) Pub Date : 2024-10-24 Rongxi Wang, Weiming Kang, Zhen Liu, Yumin Zheng, Huimin Sui, Linlin Li, Jiarou Wang, Jialin Xiang, Xingtong Peng, Xiaoyuan Chen, Zhaohui Zhu, Jingjing Zhang
Gastrointestinal stromal tumors (GISTs) are the most common stromal tumors in the gastrointestinal tract. This study was designed to evaluate a gastrin-releasing peptide receptor antagonist PET tracer, [68Ga]Ga-NOTA-RM26, and compare it with [18F]FDG PET/CT in the assessment of patients with GISTs. Methods: With institutional review board approval and informed consent, 30 patients with suspected or
-
[18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non–Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy J Nucl. Med. (IF 9.1) Pub Date : 2024-10-24 Jelena Levi, Millie Das, Minal S. Vasanawala, Deepti Behl, Martin Pomper, Patrick M. Forde, Erica Nakajima, James Sayre, Bin Shen, Hilda Cabrera, Niko Del Mar, Michele Gullen, Michele Pierini, Laura Cox, Ojaswita Lokre, Timothy Perk, Hee-Don Chae
Despite the systemic impact of both cancer and the associated immune response, immuno-PET is predominantly centered on assessment of the immune milieu within the tumor microenvironment. The aim of this study was to assess the value of [18F]F-AraG PET imaging as a noninvasive method for evaluation of system-wide immune status of patients with non–small cell lung cancer before starting immunotherapy
-
Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy J Nucl. Med. (IF 9.1) Pub Date : 2024-10-24 Adriana Amerein, Christoph Maurer, Malte Kircher, Alexander Gäble, Anne Krebold, Andreas Rinscheid, Oliver Viering, Christian H. Pfob, Ralph A. Bundschuh, Lars Behrens, Arthur JAT Braat, Ansgar Berlis, Constantin Lapa
Peptide receptor radionuclide therapy (PRRT) is a treatment option for patients with advanced meningioma. Recently, intraarterial application of the radiolabeled somatostatin receptor agonists has been introduced as an alternative to standard intravenous administration. In this study, we assessed the safety and efficacy of intraarterial PRRT in patients with advanced, progressive meningioma. Methods:
-
SNMMI Procedure Standard/EANM Practice Guideline for Brain [18F]FDG PET Imaging, Version 2.0 J Nucl. Med. (IF 9.1) Pub Date : 2024-10-17 Javier Arbizu, Silvia Morbelli, Satoshi Minoshima, Henryk Barthel, Philip Kuo, Donatienne Van Weehaeghe, Neil Horner, Patrick M. Colletti, Eric Guedj
PREAMBLE The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. The European Association of Nuclear Medicine (EANM) is a professional nonprofit medical association that facilitates communication worldwide between individuals pursuing
-
Improved Localization of Insulinomas Using 68Ga-NODAGA-Exendin-4 PET/CT J Nucl. Med. (IF 9.1) Pub Date : 2024-10-17 Marti Boss, Olof Eriksson, Kirsi Mikkola, Annemarie Eek, Maarten Brom, Mijke Buitinga, Adrienne H. Brouwers, Irina Velikyan, Beatrice Waser, Saila Kauhanen, Olof Solin, Camille Marciniak, Barbro Eriksson, Jean-Claude Reubi, Cyrielle Aveline, Damian Wild, Francois Pattou, Jean-Noel Talbot, Johannes Hofland, Anders Sundin, Pirjo Nuutila, John Hermans, Martin Gotthardt
Visual Abstract
-
Impact of 18F-FDG PET/MRI on Therapeutic Management of Women with Newly Diagnosed Breast Cancer: Results from a Prospective Double-Center Trial J Nucl. Med. (IF 9.1) Pub Date : 2024-10-10 Kai Jannusch, Lale Umutlu, Julian Kirchner, Nils-Martin Bruckmann, Janna Morawitz, Ken Herrmann, Wolfgang Peter Fendler, Ann-Kathrin Bittner, Oliver Hoffmann, Svjetlana Mohrmann, Eugen Ruckhäberle, Martin Stuschke, Werner Schmid, Frederik Giesel, Lena Häberle, Irene Esposito, Wilfried Budach, Johannes Grueneisen, Christiane Matuschek, Bernd Kowall, Andreas Stang, Gerald Antoch, Christian Buchbender
Our rationale was to investigate whether 18F-FDG PET/MRI in addition to (guideline-recommended) conventional staging leads to changes in therapeutic management in patients with newly diagnosed breast cancer and compare the diagnostic accuracy of 18F-FDG PET/MRI with that of conventional staging for determining the Union for International Cancer Control (UICC) stage. Methods: In this prospective, double-center
-
Ultrashort Oncologic Whole-Body [18F]FDG Patlak Imaging Using LAFOV PET J Nucl. Med. (IF 9.1) Pub Date : 2024-10-01 Joyce van Sluis, Johannes H. van Snick, Andor W.J.M. Glaudemans, Riemer H.J.A. Slart, Walter Noordzij, Adrienne H. Brouwers, Rudi A.J.O. Dierckx, Adriaan A. Lammertsma, Charalampos Tsoumpas, Ronald Boellaard
Methods to shorten [18F]FDG Patlak PET imaging procedures ranging from 65–90 to 20–30 min after injection, using a population-averaged input function (PIF) scaled to patient-specific image-derived input function (IDIF) values, were recently evaluated. The aim of the present study was to explore the feasibility of ultrashort 10-min [18F]FDG Patlak imaging at 55–65 min after injection using a PIF combined
-
Improving 18F-FDG PET Quantification Through a Spatial Normalization Method J Nucl. Med. (IF 9.1) Pub Date : 2024-10-01 Daewoon Kim, Seung Kwan Kang, Seong A. Shin, Hongyoon Choi, Jae Sung Lee
Quantification of 18F-FDG PET images is useful for accurate diagnosis and evaluation of various brain diseases, including brain tumors, epilepsy, dementia, and Parkinson disease. However, accurate quantification of 18F-FDG PET images requires matched 3-dimensional T1 MRI scans of the same individuals to provide detailed information on brain anatomy. In this paper, we propose a transfer learning approach
-
C-X-C Motif Chemokine Receptor 4–Directed Scintigraphy Using [99mTc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept Study J Nucl. Med. (IF 9.1) Pub Date : 2024-10-01 Johanna S. Enke, Kathrin Ritzel, Evelyn Asbach, Nic G. Reitsam, Bruno Märkl, Thomas Knösel, Denise Brüdgam, Malte Kircher, Christian H. Pfob, Ralph A. Bundschuh, Andreas Rinscheid, Bernd Nittbaur, Georgine Wienand, Margret Schottelius, Martin Reincke, Constantin Lapa, Alexander Dierks
C-X-C motif chemokine receptor 4 (CXCR4)–directed imaging has gained clinical interest in aiding clinical diagnostics in primary aldosteronism (PA). We retrospectively evaluated the feasibility of CXCR4-directed scintigraphy using the novel CXCR-4 ligand [99mTc]Tc-pentixatec in patients with PA. Methods: Six patients (mean age ± SD, 49 ± 15 y) underwent CXCR4-directed scintigraphy (including planar
-
Design, Synthesis, and Preclinical Evaluation of a High-Affinity 18F-Labeled Radioligand for Myocardial Growth Hormone Secretagogue Receptor Before and After Myocardial Infarction J Nucl. Med. (IF 9.1) Pub Date : 2024-10-01 Rebecca Sullivan, Jinqiang Hou, Lihai Yu, Benjamin Wilk, Jane Sykes, Heather Biernaski, John Butler, Michael Kovacs, Justin Hicks, Jonathan D. Thiessen, Rohan Dharmakumar, Frank S. Prato, Gerald Wisenberg, Leonard G. Luyt, Savita Dhanvantari
The peptide hormone ghrelin is produced in cardiomyocytes and acts through the myocardial growth hormone secretagogue receptor (GHSR) to promote cardiomyocyte survival. Administration of ghrelin may have therapeutic effects on post–myocardial infarction (MI) outcomes. Therefore, there is a need to develop molecular imaging probes that can track the dynamics of GHSR in health and disease to better predict
-
Molecular Imaging of p53 in Mouse Models of Cancer Using a Radiolabeled Antibody TAT Conjugate with SPECT J Nucl. Med. (IF 9.1) Pub Date : 2024-10-01 Hudson Alakonya, Sofia Koustoulidou, Samantha L. Hopkins, Mathew Veal, Javier Ajenjo, Deborah Sneddon, Gemma Dias, Michael Mosley, Julia Baguña Torres, Francesca Amoroso, Amanda Anderson, Alison H. Banham, Bart Cornelissen
Mutations of p53 protein occur in over half of all cancers, with profound effects on tumor biology. We present the first—to our knowledge—method for noninvasive visualization of p53 in tumor tissue in vivo, using SPECT, in 3 different models of cancer. Methods: Anti-p53 monoclonal antibodies were conjugated to the cell-penetrating transactivator of transcription (TAT) peptide and a metal ion chelator
-
The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for 161Tb Compared with 177Lu with a Higher Dose Response for [161Tb]Tb-DOTA-LM3 Than for [161Tb]Tb-DOTATATE J Nucl. Med. (IF 9.1) Pub Date : 2024-10-01 Kaat Spoormans, Lara Struelens, Koen Vermeulen, Marijke De Saint-Hubert, Michel Koole, Melissa Crabbé
Preclinical data have shown that 161Tb-labeled peptides targeting the somatostatin receptor are therapeutically more effective for peptide receptor radionuclide therapy than are their 177Lu-labeled counterparts. To further substantiate this enhanced therapeutic effect, we performed cellular dosimetry to quantify the absorbed dose to the cell nucleus and compared dose–response curves to evaluate differences
-
Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent 177Lu-Labeled Radiohapten J Nucl. Med. (IF 9.1) Pub Date : 2024-10-01 Brett A. Vaughn, Sang-gyu Lee, Daniela Burnes Vargas, Shin Seo, Sara S. Rinne, Hong Xu, Hong-fen Guo, Alexandre B. Le Roux, Leah Gajecki, Simone Krebs, Guangbin Yang, Ouathek Ouerfelli, Pat B. Zanzonico, Edward K. Fung, Samantha St. Jean, Sebastian E. Carrasco, Achim Jungbluth, Nai Kong V. Cheung, Steven M. Larson, Darren R. Veach, Sarah M. Cheal
Radiolabeled small-molecule DOTA-haptens can be combined with antitumor/anti-DOTA bispecific antibodies (BsAbs) for pretargeted radioimmunotherapy (PRIT). For optimized delivery of the theranostic γ- and β-emitting isotope 177Lu with DOTA-based PRIT (DOTA-PRIT), bivalent Gemini (DOTA-Bn-thiourea-PEG4-thiourea-Bn-DOTA, aka (3,6,9,12-tetraoxatetradecane-1,14-diyl)bis(DOTA-benzyl thiourea)) was developed
-
Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors J Nucl. Med. (IF 9.1) Pub Date : 2024-10-01 Andrea Galbiati, Matilde Bocci, Domenico Ravazza, Jacqueline Mock, Ettore Gilardoni, Dario Neri, Samuele Cazzamalli
Fibroblast activation protein (FAP) is abundantly expressed in the stroma of most human solid tumors. Clinical-stage radiolabeled FAP ligands are increasingly used as tools for the detection of various cancer lesions. To unleash the full therapeutic potential of FAP-targeting agents, ligands need to remain at the tumor site for several days after administration. We recently described the discovery
-
[68Ga]Ga-RAYZ-8009: A Glypican-3–Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging—A First-in-Human Case Series J Nucl. Med. (IF 9.1) Pub Date : 2024-10-01 Alex J. Poot, Constantin Lapa, Wolfgang A. Weber, Marnix G.E.H. Lam, Matthias Eiber, Alexander Dierks, Ralph A. Bundschuh, Arthur J.A.T. Braat
To date, the imaging and diagnosis of hepatocellular carcinoma (HCC) rely on CT/MRI, which have well-known limitations. Glypican-3 (GPC3) is a cell surface receptor highly expressed by HCC but not by normal or cirrhotic liver tissue. Here we report initial clinical results of GPC3-targeted PET imaging with [68Ga]Ga-DOTA-RYZ-GPC3 (RAYZ-8009), a peptide-based GPC3 ligand in patients with known or suspected
-
Dual Somatostatin Receptor/18F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors J Nucl. Med. (IF 9.1) Pub Date : 2024-10-01 Ur Metser, Jose E. Nunez, David Chan, Roshini Kulanthaivelu, Vanessa Murad, Anna T. Santiago, Simron Singh
Our purpose was to prospectively assess the distribution of NETPET scores in well-differentiated (WD) grade 2 and 3 gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) and to determine the impact of the NETPET score on clinical management. Methods: This single-arm, institutional ethics review board–approved prospective study included 40 patients with histologically proven WD GEP NETs. 68Ga-DOTATATE
-
Quantitative SPECT/CT Metrics in Early Prediction of [177Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients J Nucl. Med. (IF 9.1) Pub Date : 2024-10-01 Onur Tuncer, Daniel Steinberger, Joseph Steiner, Madeleine Hinojos, Stephanie Y. Rhee, Brad Humphrey, Farhad Jafari, Zuzan Cayci
Our objective is to explore quantitative imaging markers for early prediction of treatment response in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) undergoing [177Lu]Lu-DOTATATE therapy. By doing so, we aim to enable timely switching to more effective therapies in order to prevent time-resource waste and minimize toxicities. Methods: Patients diagnosed with unresectable or
-
Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [18F]PSMA-1007 PET/CT J Nucl. Med. (IF 9.1) Pub Date : 2024-10-01 Matteo Bauckneht, Francesca D’Amico, Domenico Albano, Michele Balma, Camilla Cabrini, Francesco Dondi, Tania Di Raimondo, Virginia Liberini, Luca Sofia, Simona Peano, Mattia Riondato, Giuseppe Fornarini, Riccardo Laudicella, Luca Carmisciano, Egesta Lopci, Roberta Zanca, Marcello Rodari, Stefano Raffa, Maria Isabella Donegani, Daniela Dubois, Leonardo Peñuela, Cecilia Marini, Francesco Bertagna, Alberto
Unspecific bone uptake (UBU) related to [18F]PSMA-1007 PET/CT imaging represents a clinical challenge. We aimed to assess whether a combination of clinical, biochemical, and imaging parameters could predict skeletal metastases in patients with [18F]PSMA-1007 bone focal uptake, aiding in result interpretation. Methods: We retrospectively analyzed [18F]PSMA-1007 PET/CT performed in hormone-sensitive